<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Cancer Chemother Pharmacol</journal-id><journal-id journal-id-type="iso-abbrev">Cancer Chemother. Pharmacol</journal-id><journal-title-group><journal-title>Cancer Chemotherapy and Pharmacology</journal-title></journal-title-group><issn pub-type="ppub">0344-5704</issn><issn pub-type="epub">1432-0843</issn><publisher><publisher-name>Springer Berlin Heidelberg</publisher-name><publisher-loc>Berlin/Heidelberg</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28032129</article-id><article-id pub-id-type="pmc">5225209</article-id><article-id pub-id-type="publisher-id">3220</article-id><article-id pub-id-type="doi">10.1007/s00280-016-3220-6</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>First-dose and steady-state pharmacokinetics of orally administered crizotinib in children with solid tumors: a report on ADVL0912 from the Children&#x02019;s Oncology Group Phase 1/Pilot Consortium</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Balis</surname><given-names>Frank M.</given-names></name><address><phone>267-426-5414</phone><email>balisf@email.chop.edu</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Thompson</surname><given-names>Patrick A.</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Mosse</surname><given-names>Yael P.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Blaney</surname><given-names>Susan M.</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Minard</surname><given-names>Charles G.</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Weigel</surname><given-names>Brenda J.</given-names></name><xref ref-type="aff" rid="Aff4">4</xref><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Fox</surname><given-names>Elizabeth</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label>The Children&#x02019;s Hospital of Philadelphia, 3501 Civic Center Blvd, CTRB-4024, Philadelphia, PA 19104 USA </aff><aff id="Aff2"><label>2</label>University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC 27599 USA </aff><aff id="Aff3"><label>3</label>Baylor College of Medicine, Dan L Duncan Comprehensive Cancer Center, Houston, TX 77030 USA </aff><aff id="Aff4"><label>4</label>University of Minnesota, Masonic Cancer Center, Minneapolis, MN 55455 USA </aff><aff id="Aff5"><label>5</label>The Children&#x02019;s Oncology Group Operations Center, Monrovia, CA 91016 USA </aff></contrib-group><pub-date pub-type="epub"><day>28</day><month>12</month><year>2016</year></pub-date><pub-date pub-type="pmc-release"><day>28</day><month>12</month><year>2016</year></pub-date><pub-date pub-type="ppub"><year>2017</year></pub-date><volume>79</volume><issue>1</issue><fpage>181</fpage><lpage>187</lpage><history><date date-type="received"><day>2</day><month>12</month><year>2016</year></date><date date-type="accepted"><day>8</day><month>12</month><year>2016</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2016</copyright-statement><license license-type="OpenAccess"><license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.</license-p></license></permissions><abstract id="Abs1"><sec><title>Purpose</title><p>
Characterize the pharmacokinetics of oral crizotinib in children with cancer.</p></sec><sec><title>Methods</title><p>Sixty-four children with solid tumors or anaplastic large-cell lymphoma (ALCL) enrolled on a phase 1/2 trial of the ALK, MET and ROS1 inhibitor, crizotinib, had pharmacokinetic sampling after the first dose (<italic>n</italic>&#x000a0;=&#x000a0;15) or at steady state (<italic>n</italic>&#x000a0;=&#x000a0;49). Dose levels studied were 100, 130, 165, 215, 280 and 365&#x000a0;mg/m<sup>2</sup>/dose administered twice daily. Two capsule and two oral liquid formulations were used over the course of the trial. Crizotinib was quantified with a validated HPLC/tandem mass spectrometry method with a lower limit of detection of 0.2&#x000a0;ng/mL. Pharmacokinetic parameters were derived using non-compartmental analysis.</p></sec><sec><title>Results</title><p>Time to peak plasma concentration was 4&#x000a0;h. At 280&#x000a0;mg/m<sup>2</sup> (MTD), mean (&#x000b1;SD) steady-state peak plasma concentration was 717&#x000a0;&#x000b1;&#x000a0;201&#x000a0;ng/mL, and steady-state trough plasma concentration was 480&#x000a0;&#x000b1;&#x000a0;176&#x000a0;ng/mL. At steady state, AUC<sub>0&#x02013;<italic>&#x003c4;</italic></sub> was proportional to dose over the dose range of 215&#x02013;365&#x000a0;mg/m<sup>2</sup>/dose. Apparent clearance of crizotinib was 731&#x000a0;&#x000b1;&#x000a0;241&#x000a0;mL/min/m<sup>2</sup>. Steady-state AUC<sub>0&#x02013;<italic>&#x003c4;</italic></sub> at 280&#x000a0;mg/m<sup>2</sup>/dose was 2.5-fold higher than the AUC<sub>0&#x02013;<italic>&#x0221e;</italic></sub> in adults receiving 250&#x000a0;mg (~140&#x000a0;mg/m<sup>2</sup>). Age, sex and drug formulation do not account for the inter-subject variability in AUC<sub>0&#x02013;<italic>&#x003c4;</italic></sub> at steady state. The accumulation index was 4.9, and the half-life estimated from the accumulation index was 36&#x000a0;h.</p></sec><sec><title>Conclusions</title><p>The pharmacokinetics of oral crizotinib in children is similar to that in adults. Steady-state trough-free crizotinib concentrations in plasma at the MTD exceed inhibitory concentrations of crizotinib in ALCL cell lines.</p></sec><sec><title>ClinicalTrials.gov identifier</title><p>NCT00939770.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Crizotinib</kwd><kwd>Pharmacokinetics</kwd><kwd>Childhood cancer</kwd><kwd>Children</kwd><kwd>ALK</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100004319</institution-id><institution>Pfizer</institution></institution-wrap></funding-source></award-group><award-group><funding-source><institution>Children's Oncology Group</institution></funding-source></award-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000054</institution-id><institution>National Cancer Institute</institution></institution-wrap></funding-source><award-id>UM1 CA097452</award-id></award-group><award-group><funding-source><institution>Cookies for Kid's Cancer Foundation</institution></funding-source></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer-Verlag Berlin Heidelberg 2017</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p>Crizotinib is a small molecule inhibitor of multiple tyrosine kinases, including the anaplastic lymphoma kinase encoded by the <italic>ALK</italic> gene, hepatocyte growth factor receptor (c-met) encoded by <italic>MET</italic> and the tyrosine kinase, ROS encoded by <italic>ROS1</italic> [<xref ref-type="bibr" rid="CR1">1</xref>]. Crizotinib is approved worldwide for the treatment of the subset of non-small-cell lung cancers (NSCLC) with rearrangements involving <italic>ALK</italic> [<xref ref-type="bibr" rid="CR2">2</xref>&#x02013;<xref ref-type="bibr" rid="CR4">4</xref>]. Responses to crizotinib have also been reported in patients with anaplastic large-cell lymphoma (ALCL) and inflammatory myofibroblastic tumors [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR6">6</xref>], both of which have a high incidence of <italic>ALK</italic> rearrangements, especially in children [<xref ref-type="bibr" rid="CR7">7</xref>].</p><p>The adult recommended oral dose of crizotinib is 250&#x000a0;mg twice daily, which is equivalent to approximately 140&#x000a0;mg/m<sup>2</sup>/dose. The pharmacokinetics of crizotinib in adults has been studied after a single dose and at steady state (&#x02265;15&#x000a0;days) in patients with NSCLC using 250-mg formulated capsules and after a single 50-mg dose of an experimental intravenous formulation or a single 250-mg dose of three oral formulations [formulated capsules (FC), powder in capsules (PIC) and immediate-release tablets (IRT)] in healthy volunteers [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR9">9</xref>]. The mean (C.V.) clearance (CL) of crizotinib was 47 (18%) L/h, the volume of distribution at steady state was 1770 (18%) L and the half-life (<italic>T</italic>
<sub>1/2</sub>) was 39 (16%) h, following the intravenous dose. The absolute bioavailability (<italic>F</italic>) of the IRT formulation was 43%. After oral administration, the time to peak concentration (<italic>T</italic>
<sub>max</sub>) was 5&#x000a0;h, the peak plasma concentration (<italic>C</italic>
<sub>max</sub>) was 120&#x02013;135&#x000a0;ng/mL, and the area under the plasma concentration&#x02013;time curve extrapolated to infinity (AUC<sub>0&#x02013;<italic>&#x0221e;</italic></sub>) was 2700&#x02013;2900&#x000a0;ng&#x000a0;h/mL. The three oral formulations were bioequivalent. The accumulation index (<italic>R</italic>) at steady state was 4.5.</p><p>A separate phase 1/2 trial of oral crizotinib administered twice daily using PIC, FC and two liquid formulations was conducted in children with solid tumors and ALCL [<xref ref-type="bibr" rid="CR6">6</xref>]. Dose levels studied were 100, 130, 165, 215, 280 and 365&#x000a0;mg/m<sup>2</sup>/dose, and the maximum tolerated dose (MTD) was 280&#x000a0;mg/m<sup>2</sup>/dose, which is twofold higher than the adult recommended dose. Steady-state pharmacokinetic parameters in 18 children receiving 280&#x000a0;mg/m<sup>2</sup>/dose were briefly summarized in the previously reported phase 1/2 trial results [<xref ref-type="bibr" rid="CR6">6</xref>]. This report describes in more detail the pharmacokinetics of crizotinib in children enrolled on the phase 1/2 trial and includes 64 subjects treated at the six dose levels and studied after the first dose (<italic>n</italic>&#x000a0;=&#x000a0;15) or at steady state (<italic>n</italic>&#x000a0;=&#x000a0;49). The previously reported 18 patients are included in this cohort.</p></sec><sec id="Sec2"><title>Materials and methods</title><sec id="Sec3"><title>Drug</title><p>Crizotinib was provided by Pfizer Inc. (New York, NY) in four formulations over the course of the phase 1/2 clinical trial:<list list-type="bullet"><list-item><p>PIC in 10, 50 and 100&#x000a0;mg strengths,</p></list-item><list-item><p>FC (commercial formulation) in 150, 200 and 250&#x000a0;mg strengths,</p></list-item><list-item><p>Powder in bottles (PIB) containing 2500&#x000a0;mg in a 4&#x000a0;oz vial that is reconstituted to a 25&#x000a0;mg/mL suspension,</p></list-item><list-item><p>Oral solution (OS) containing 25&#x000a0;mg/mL in a sweetened and flavored aqueous vehicle. OS replaced PIB.</p></list-item></list>The OS is bioequivalent to FC in adults (Pfizer, data on file).</p></sec><sec id="Sec4"><title>Study design</title><p>The pediatric phase 1/2 trial of crizotinib (ADVL0912) was sponsored by Pfizer Inc. and conducted within the twenty-one member institutions of the Pediatric Phase 1 and Pilot Consortium plus five additional sites. The protocol was conducted in accordance with the Declaration of Helsinki and approved by the Institutional Review Boards at all participating institutions. Informed consent was obtained from all subjects who were 18&#x000a0;years or older or from the parents of subjects under the age of 18&#x000a0;years. The eligibility criteria, trial design and subject cohorts have been previously reported [<xref ref-type="bibr" rid="CR6">6</xref>]. Crizotinib was administered orally, twice daily, continuously at doses of 100, 130, 165, 215, 280 and 365&#x000a0;mg/m<sup>2</sup>/dose on the phase 1 dose escalation portion of the trial and at a dose of 280&#x000a0;mg/m<sup>2</sup>/dose after this dose was identified as the MTD. For this report, the administered dose per m<sup>2</sup> was calculated by dividing the patient&#x02019;s dose (in mg) that was determined by a dosing nomogram in the protocol by their body surface area. In subjects receiving capsules, the administered dose per m<sup>2</sup> often deviated slightly from the dose level because of dosing limitations imposed by capsule size.</p></sec><sec id="Sec5"><title>Sample collection and processing</title><p>Subjects studied after their first dose of crizotinib had 2&#x000a0;mL blood samples collected into potassium EDTA-containing tubes prior to the dose and 0.5, 1, 2, 4, 6, 8 and 24&#x000a0;h after the morning dose. The evening dose of crizotinib was not administered on day 1 in these subjects. A trough blood sample was also drawn prior to the morning dose on day 7. Subjects studied at steady state (day 15&#x02013;28 of cycle 1) had blood samples drawn prior to their first dose on day 1, prior to the morning dose at steady state and then 1, 2, 4, 6&#x02013;8&#x000a0;h after the morning dose. Blood samples were protected from light and placed on ice. Plasma was separated by centrifugation at 1700<italic>g</italic> for 10&#x000a0;min at 4&#x000a0;&#x000b0;C and immediately frozen at &#x02212;20 to &#x02212;70&#x000a0;&#x000b0;C until assayed.</p></sec><sec id="Sec6"><title>Crizotinib assay</title><p>Plasma concentrations of crizotinib were quantified by Covance Bioanalytical Services (Indianapolis, IN) using a previously described, validated high-pressure liquid chromatography (HPLC), tandem mass spectroscopic method with a lower limit of quantification of 0.2&#x000a0;ng/mL [<xref ref-type="bibr" rid="CR8">8</xref>].</p></sec><sec id="Sec7"><title>Pharmacokinetic analysis</title><p>Crizotinib plasma concentration&#x02013;time data were analyzed using model-independent methods. The area under the crizotinib plasma concentration&#x02013;time curve to the last measured time point (AUC<sub>0&#x02013;tlast</sub>) was derived using the linear trapezoidal rule. The limited sampling duration did not allow for accurate estimation of the terminal slope of the plasma concentration&#x02013;time curve after the first dose. As a result, the terminal <italic>T</italic>
<sub>1/2</sub> could not derived, and the AUC could not be accurately extrapolated to infinity (AUC<sub>0&#x02013;<italic>&#x0221e;</italic></sub>) in the subjects studied after the first dose. For calculating the steady-state AUC over the 12-h dosing interval (<italic>&#x003c4;</italic>), which is equivalent to AUC<sub>0&#x02013;<italic>&#x0221e;</italic></sub> after a single dose, the trough concentration drawn prior to the dose was also used as the 12-h post-dose concentration. The average plasma crizotinib concentration at steady state (<inline-formula id="IEq4"><alternatives><tex-math id="M1">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$ C_{\text{ave}}^{\text{ss}} $$\end{document}</tex-math><mml:math id="M2"><mml:msubsup><mml:mi>C</mml:mi><mml:mrow><mml:mtext>ave</mml:mtext></mml:mrow><mml:mtext>ss</mml:mtext></mml:msubsup></mml:math><inline-graphic xlink:href="280_2016_3220_Article_IEq4.gif"/></alternatives></inline-formula>) was derived by dividing the AUC<sub>0&#x02013;<italic>&#x003c4;</italic></sub> by <italic>&#x003c4;</italic> (12&#x000a0;h), and the apparent clearance (CL/F) of crizotinib is the dose divided by AUC<sub>0&#x02013;<italic>&#x003c4;</italic></sub>.</p><p>
<italic>R</italic> was derived by dividing the day 7 steady-state trough concentration (<inline-formula id="IEq5"><alternatives><tex-math id="M3">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$ C_{{12{\text{h}}}}^{\text{ss}} $$\end{document}</tex-math><mml:math id="M4"><mml:msubsup><mml:mi>C</mml:mi><mml:mrow><mml:mrow><mml:mn>12</mml:mn><mml:mtext>h</mml:mtext></mml:mrow></mml:mrow><mml:mtext>ss</mml:mtext></mml:msubsup></mml:math><inline-graphic xlink:href="280_2016_3220_Article_IEq5.gif"/></alternatives></inline-formula>) by the concentration 12&#x000a0;h after the first dose (C<sub>12h</sub>). C<sub>12h</sub> was estimated by extrapolation using the slope estimated from the Ln transformed 8 and 24&#x000a0;h plasma concentrations. <italic>T</italic>
<sub>1/2</sub> was estimated from the mean <italic>R</italic> by rearranging the equation for calculating <italic>R</italic> from the <italic>T</italic>
<sub>1/2</sub>:<disp-formula id="Equa"><alternatives><tex-math id="M5">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$ R = \frac{1}{{\left[ {1 - {\text{e}}^{{\left( { - \frac{0.693}{{t_{1/2} }} \cdot \tau } \right)}} } \right]}}.$$\end{document}</tex-math><mml:math id="M6" display="block"><mml:mrow><mml:mi>R</mml:mi><mml:mo>=</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:mfenced close="]" open="[" separators=""><mml:mrow><mml:mn>1</mml:mn><mml:mo>-</mml:mo><mml:msup><mml:mrow><mml:mtext>e</mml:mtext></mml:mrow><mml:mfenced close=")" open="(" separators=""><mml:mrow><mml:mo>-</mml:mo><mml:mfrac><mml:mrow><mml:mn>0.693</mml:mn></mml:mrow><mml:msub><mml:mi>t</mml:mi><mml:mrow><mml:mn>1</mml:mn><mml:mo stretchy="false">/</mml:mo><mml:mn>2</mml:mn></mml:mrow></mml:msub></mml:mfrac><mml:mo>&#x000b7;</mml:mo><mml:mi mathvariant="italic">&#x003c4;</mml:mi></mml:mrow></mml:mfenced></mml:msup></mml:mrow></mml:mfenced></mml:mfrac><mml:mo>.</mml:mo></mml:mrow></mml:math><graphic xlink:href="280_2016_3220_Article_Equa.gif" position="anchor"/></alternatives></disp-formula>
</p></sec><sec id="Sec8"><title>Statistical analysis</title><p>A linear multiple regression model was used to assess the relationship between AUC<sub>0&#x02013;<italic>&#x003c4;</italic></sub> normalized to the administered dose/m<sup>2</sup> at steady state and age, gender and drug formulation using the <italic>lm</italic> function in R statistical software package (The R Foundation for Statistical Computing, <ext-link ext-link-type="uri" xlink:href="http://www.R-project.org">http://www.R-project.org</ext-link>).</p></sec></sec><sec id="Sec9"><title>Results</title><sec id="Sec10"><title>Subjects</title><p>Seventy-five subjects had pharmacokinetic blood samples drawn after their first dose of crizotinib (<italic>n</italic>&#x000a0;=&#x000a0;15) or at steady state immediately prior to and after their morning dose (<italic>n</italic>&#x000a0;=&#x000a0;60). The data from 11 subjects studied at steady state were not evaluable because the trough sample was not drawn at the appropriate time (<italic>n</italic>&#x000a0;=&#x000a0;6), samples were missed (<italic>n</italic>&#x000a0;=&#x000a0;2), the dose of crizotinib had been reduced for prior toxicity (<italic>n</italic>&#x000a0;=&#x000a0;1), the dose was spit out (<italic>n</italic>&#x000a0;=&#x000a0;1), or the preceding evening dose had not been given (<italic>n</italic>&#x000a0;=&#x000a0;1). The characteristics of the 64 subjects with evaluable data are listed in Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>.<table-wrap id="Tab1"><label>Table&#x000a0;1</label><caption><p>Subject characteristics</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left">First dose</th><th align="left">Steady state</th></tr></thead><tbody><tr><td align="left">Number</td><td align="left">15</td><td align="left">49</td></tr><tr><td align="left">Median (range) age (year)</td><td align="left">11.9 (5.7&#x02013;21.4)</td><td align="left">10.1 (2.6&#x02013;22)</td></tr><tr><td align="left">Male/female</td><td align="left">10:5</td><td align="left">23:26</td></tr><tr><td align="left">Dose level (mg/m<sup>2</sup>/dose)</td><td align="left"/><td align="left"/></tr><tr><td align="left">&#x000a0;100</td><td align="left">3</td><td align="left"/></tr><tr><td align="left">&#x000a0;130</td><td align="left">3</td><td align="left"/></tr><tr><td align="left">&#x000a0;165</td><td align="left">7</td><td align="left">1</td></tr><tr><td align="left">&#x000a0;215</td><td align="left">2</td><td align="left">5</td></tr><tr><td align="left">&#x000a0;280</td><td align="left"/><td align="left">36</td></tr><tr><td align="left">&#x000a0;365</td><td align="left"/><td align="left">7</td></tr><tr><td align="left">Formulation</td><td align="left"/><td align="left"/></tr><tr><td align="left">&#x000a0;Powder in capsule</td><td align="left">14</td><td align="left">28<sup>a</sup>
</td></tr><tr><td align="left">&#x000a0;Powder in bottle</td><td align="left">1</td><td align="left">8</td></tr><tr><td align="left">&#x000a0;Formulated capsule</td><td align="left"/><td align="left">9</td></tr><tr><td align="left">&#x000a0;Oral solution</td><td align="left"/><td align="left">4</td></tr></tbody></table><table-wrap-foot><p>
<sup>a</sup>One subject received a combination of powder in capsule and powder in bottle</p></table-wrap-foot></table-wrap>
</p></sec><sec id="Sec11"><title>First-dose pharmacokinetics</title><p>Figure&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref> shows the mean plasma crizotinib concentration&#x02013;time profiles for subjects studied after the first dose at four dose levels, and Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref> provides the pharmacokinetic parameters. Figure&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref> shows the relationship of dose to AUC<sub>0&#x02013;tlast</sub>. AUC<sub>0&#x02013;tlast</sub> does not appear to increase in proportion to the dose over the twofold dose range (100&#x02013;215&#x000a0;mg/m<sup>2</sup>). This may reflect the substantial inter-subject variability (C.V. for the AUC<sub>0&#x02013;tlast</sub> normalized to the administered dose per m<sup>2</sup> was 105%), as well as the small cohort size and the influence of an outlier at 130&#x000a0;mg/m<sup>2</sup>/dose (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>). The mean <italic>R</italic> across the four dose levels was 4.9, and the <italic>T</italic>
<sub>1/2</sub> of crizotinib estimated from the mean <italic>R</italic> was 36&#x000a0;h.<fig id="Fig1"><label>Fig.&#x000a0;1</label><caption><p>Plasma concentration&#x02013;time profiles in subjects studied after the first dose and at steady state at 6 dose levels. <italic>Points</italic> are the geometric mean and <italic>error bars</italic> are the SD</p></caption><graphic xlink:href="280_2016_3220_Fig1_HTML" id="MO2"/></fig>
<table-wrap id="Tab2"><label>Table&#x000a0;2</label><caption><p>Pharmacokinetic parameters for oral crizotinib studied after the first dose in children with solid tumors or ALCL at four dose levels ranging from 100 to 215&#x000a0;mg/m<sup>2</sup>/dose</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Dose level (mg/m<sup>2</sup>/dose)</th><th align="left">Number of subjects</th><th align="left">
<italic>C</italic>
<sub>max</sub> (ng/mL)</th><th align="left">
<italic>T</italic>
<sub>max</sub> (h)</th><th align="left">AUC<sub>0&#x02013;tlast</sub> (ng&#x000a0;h/mL)</th><th align="left">
<italic>R</italic>
</th></tr></thead><tbody><tr><td align="left">100</td><td char="." align="char">3</td><td char="&#x000b1;" align="char">144&#x000a0;&#x000b1;&#x000a0;97</td><td char="&#x000b1;" align="char">3.3&#x000a0;&#x000b1;&#x000a0;2.2</td><td char="&#x000b1;" align="char">1260&#x000a0;&#x000b1;&#x000a0;320</td><td char="&#x000b1;" align="char">2.8&#x000a0;&#x000b1;&#x000a0;1.6</td></tr><tr><td align="left">130</td><td char="." align="char">3</td><td char="&#x000b1;" align="char">236&#x000a0;&#x000b1;&#x000a0;217</td><td char="&#x000b1;" align="char">4.7&#x000a0;&#x000b1;&#x000a0;1.1</td><td char="&#x000b1;" align="char">3300&#x000a0;&#x000b1;&#x000a0;3913</td><td char="&#x000b1;" align="char">5.8&#x000a0;&#x000b1;&#x000a0;2.9</td></tr><tr><td align="left">165</td><td char="." align="char">7</td><td char="&#x000b1;" align="char">145&#x000a0;&#x000b1;&#x000a0;70</td><td char="&#x000b1;" align="char">3.7&#x000a0;&#x000b1;&#x000a0;2.4</td><td char="&#x000b1;" align="char">1208&#x000a0;&#x000b1;&#x000a0;558</td><td char="&#x000b1;" align="char">5.2&#x000a0;&#x000b1;&#x000a0;2.1</td></tr><tr><td align="left">215</td><td char="." align="char">2</td><td char="&#x000b1;" align="char">196&#x000a0;&#x000b1;&#x000a0;60</td><td char="&#x000b1;" align="char">4.0&#x000a0;&#x000b1;&#x000a0;0</td><td char="&#x000b1;" align="char">2820&#x000a0;&#x000b1;&#x000a0;1890</td><td char="&#x000b1;" align="char">5.0&#x000a0;&#x000b1;&#x000a0;2.3</td></tr></tbody></table><table-wrap-foot><p>Fourteen of the 15 subjects received the PIC formulation. Values represent the mean&#x000a0;&#x000b1;&#x000a0;SD</p></table-wrap-foot></table-wrap>
<fig id="Fig2"><label>Fig.&#x000a0;2</label><caption><p>Relationship between AUC to the last measured time point (24&#x000a0;h) for subjects studied after the first dose or AUC over the 12-h dosing interval at steady state and the administered dose of oral crizotinib normalized to subject&#x02019;s body surface area</p></caption><graphic xlink:href="280_2016_3220_Fig2_HTML" id="MO3"/></fig>
</p></sec><sec id="Sec12"><title>Steady-state pharmacokinetics</title><p>The crizotinib plasma concentration&#x02013;time profile over the 12-h dosing interval at steady state for the dose levels ranging from 165 to 365&#x000a0;mg/m<sup>2</sup> is shown in Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>, and the mean (&#x000b1;SD) steady-state pharmacokinetic parameters are listed in Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>. At steady state, the increase in AUC<sub>0&#x02013;<italic>&#x003c4;</italic></sub> is dose-proportional over the narrow dose range (215 to 365&#x000a0;mg/m<sup>2</sup>). The variability appears to be lower at steady state (C.V. for the AUC<sub>0&#x02013;<italic>&#x003c4;</italic></sub> normalized to the administered dose per m<sup>2</sup> was 30%) than after the first dose. The mean (&#x000b1;SD) CL/F of crizotinib after oral dosing in children was 731&#x000a0;&#x000b1;&#x000a0;241&#x000a0;mL/min/m<sup>2</sup>. The ratio of the steady-state peak plasma concentration (<inline-formula id="IEq6"><alternatives><tex-math id="M7">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$ C_{ \hbox{max} }^{\text{ss}} $$\end{document}</tex-math><mml:math id="M8"><mml:msubsup><mml:mi>C</mml:mi><mml:mrow><mml:mtext>max</mml:mtext></mml:mrow><mml:mtext>ss</mml:mtext></mml:msubsup></mml:math><inline-graphic xlink:href="280_2016_3220_Article_IEq6.gif"/></alternatives></inline-formula>) to <inline-formula id="IEq7"><alternatives><tex-math id="M9">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$ C_{{12{\text{h}}}}^{\text{ss}} $$\end{document}</tex-math><mml:math id="M10"><mml:msubsup><mml:mi>C</mml:mi><mml:mrow><mml:mrow><mml:mn>12</mml:mn><mml:mtext>h</mml:mtext></mml:mrow></mml:mrow><mml:mtext>ss</mml:mtext></mml:msubsup></mml:math><inline-graphic xlink:href="280_2016_3220_Article_IEq7.gif"/></alternatives></inline-formula> at the 280&#x000a0;mg/m<sup>2</sup> dose level (<italic>n</italic>&#x000a0;=&#x000a0;36) was 1.6&#x000a0;&#x000b1;&#x000a0;0.5, which reflects the intra-subject variation in plasma crizotinib concentrations over the dosing interval at steady state.<table-wrap id="Tab3"><label>Table&#x000a0;3</label><caption><p>Pharmacokinetic parameters for oral crizotinib studied at steady state in children with solid tumors or ALCL at four dose levels ranging from 165 to 365&#x000a0;mg/m<sup>2</sup>/dose</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Dose level (mg/m<sup>2</sup>/dose)</th><th align="left">Number of subjects</th><th align="left">
<italic>C</italic>
<sub>max</sub> (ng/mL)</th><th align="left">
<italic>T</italic>
<sub>max</sub> (h)</th><th align="left">AUC<sub>0&#x02013;<italic>&#x003c4;</italic></sub> (ng&#x000a0;h/mL)</th><th align="left">
<inline-formula id="IEq13"><alternatives><tex-math id="M11">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$ C_{\text{ave}}^{\text{ss}} $$\end{document}</tex-math><mml:math id="M12"><mml:msubsup><mml:mi>C</mml:mi><mml:mrow><mml:mtext>ave</mml:mtext></mml:mrow><mml:mtext>ss</mml:mtext></mml:msubsup></mml:math><inline-graphic xlink:href="280_2016_3220_Article_IEq13.gif"/></alternatives></inline-formula> (ng/mL)</th><th align="left">CL/F (mL/min/m<sup>2</sup>)</th><th align="left">
<inline-formula id="IEq14"><alternatives><tex-math id="M13">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$ C_{{12{\text{h}}}}^{\text{ss}} $$\end{document}</tex-math><mml:math id="M14"><mml:msubsup><mml:mi>C</mml:mi><mml:mrow><mml:mrow><mml:mn>12</mml:mn><mml:mtext>h</mml:mtext></mml:mrow></mml:mrow><mml:mtext>ss</mml:mtext></mml:msubsup></mml:math><inline-graphic xlink:href="280_2016_3220_Article_IEq14.gif"/></alternatives></inline-formula> (ng/mL)</th></tr></thead><tbody><tr><td align="left">165</td><td char="." align="char">1</td><td align="left">294</td><td align="left">6</td><td align="left">2950</td><td align="left">246</td><td align="left">735</td><td align="left">205</td></tr><tr><td align="left">215</td><td char="." align="char">5</td><td align="left">601&#x000a0;&#x000b1;&#x000a0;118</td><td align="left">4.0&#x000a0;&#x000b1;&#x000a0;1.4</td><td align="left">5630&#x000a0;&#x000b1;&#x000a0;1370</td><td align="left">469&#x000a0;&#x000b1;&#x000a0;114</td><td align="left">652&#x000a0;&#x000b1;&#x000a0;159</td><td align="left">354&#x000a0;&#x000b1;&#x000a0;133</td></tr><tr><td align="left">280</td><td char="." align="char">36</td><td align="left">717&#x000a0;&#x000b1;&#x000a0;201</td><td align="left">3.8&#x000a0;&#x000b1;&#x000a0;1.7</td><td align="left">6990&#x000a0;&#x000b1;&#x000a0;2080</td><td align="left">582&#x000a0;&#x000b1;&#x000a0;173</td><td align="left">736&#x000a0;&#x000b1;&#x000a0;255</td><td align="left">480&#x000a0;&#x000b1;&#x000a0;176</td></tr><tr><td align="left">365</td><td char="." align="char">7</td><td align="left">972&#x000a0;&#x000b1;&#x000a0;210</td><td align="left">2.1&#x000a0;&#x000b1;&#x000a0;0.1</td><td align="left">8770&#x000a0;&#x000b1;&#x000a0;2740</td><td align="left">731&#x000a0;&#x000b1;&#x000a0;228</td><td align="left">731&#x000a0;&#x000b1;&#x000a0;223</td><td align="left">650&#x000a0;&#x000b1;&#x000a0;330</td></tr></tbody></table><table-wrap-foot><p>Values represent the mean&#x000a0;&#x000b1;&#x000a0;SD</p></table-wrap-foot></table-wrap>
</p><p>A multiple regression analysis evaluating the impact of age, gender and drug formulation on the AUC<sub>0&#x02013;<italic>&#x003c4;</italic></sub> normalized to the administered dose per m<sup>2</sup> at steady state in 49 subjects demonstrated that these characteristics did not account for the variability in AUC<sub>0&#x02013;<italic>&#x003c4;</italic></sub> (multiple <italic>R</italic>
<sup>2</sup>&#x000a0;=&#x000a0;0.11; <italic>p</italic>&#x000a0;=&#x000a0;0.40). Figure&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref> shows the relationship between the normalized AUC<sub>0&#x02013;<italic>&#x003c4;</italic></sub> and age, gender and drug formulation.<fig id="Fig3"><label>Fig.&#x000a0;3</label><caption><p>Relationship of gender (<italic>left</italic>) and age by crizotinib formulation (<italic>right</italic>) to the AUC<sub>0&#x02013;<italic>&#x003c4;</italic></sub> at steady state normalized to the administered dose per m<sup>2</sup>
</p></caption><graphic xlink:href="280_2016_3220_Fig3_HTML" id="MO4"/></fig>
</p></sec></sec><sec id="Sec13"><title>Discussion</title><p>We characterized the pharmacokinetics of orally administered crizotinib in children after the first dose and at steady state (&#x02265;14&#x000a0;days of continuous twice daily dosing), at 6 dose levels ranging from 100 to 365&#x000a0;mg/m<sup>2</sup>/dose using four drug formulations. Crizotinib was dosed based on body surface area using a dosing nomogram. Despite differences in study design and sampling times, the pharmacokinetics of crizotinib in children appears to be similar to adults. The CL/F of crizotinib in adults was 850&#x000a0;mL/min/m<sup>2</sup> after a single fixed 250-mg dose in healthy volunteers and 600&#x000a0;mL/min/m<sup>2</sup> at steady state in adults with NSCLC [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR9">9</xref>]. These values are comparable to the mean CL/F at steady state in children of 730&#x000a0;mL/min/m<sup>2</sup>. The <inline-formula id="IEq8"><alternatives><tex-math id="M15">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$ C_{ \hbox{max} }^{\text{ss}} $$\end{document}</tex-math><mml:math id="M16"><mml:msubsup><mml:mi>C</mml:mi><mml:mrow><mml:mtext>max</mml:mtext></mml:mrow><mml:mtext>ss</mml:mtext></mml:msubsup></mml:math><inline-graphic xlink:href="280_2016_3220_Article_IEq8.gif"/></alternatives></inline-formula> in adults with NSCLC and children is also comparable when adjusted for differences in the dose.</p><p>Blood sampling after a single oral 250-mg dose of crizotinib in healthy volunteers extended to 144&#x000a0;h, which allows for an accurate determination of the 35&#x000a0;h terminal <italic>T</italic>
<sub>1/2</sub> [<xref ref-type="bibr" rid="CR8">8</xref>]. It is not feasible to withhold crizotinib dosing for 6 d to allow for extended blood sampling in children with cancer, and estimating the <italic>T</italic>
<sub>1/2</sub> from the samples collected over 24&#x000a0;h yields a mean <italic>T</italic>
<sub>1/2</sub> of 11&#x000a0;h, which is an underestimation of the true <italic>T</italic>
<sub>1/2</sub> rather than a true difference in the disposition of crizotinib in children versus adults. The <italic>R</italic> calculated from the C<sub>12h</sub> after the first dose and the day 7 trough concentration in children was 4.9, which is similar to 4.5 in adult [<xref ref-type="bibr" rid="CR9">9</xref>], and the <italic>T</italic>
<sub>1/2</sub> estimated from the mean <italic>R</italic> in children was 36&#x000a0;h, which is similar to the <italic>T</italic>
<sub>1/2</sub> in adult healthy volunteers. Although this is an indirect method of estimating the <italic>T</italic>
<sub>1/2</sub>, it is likely to be more accurate than estimating it directly from the concentration&#x02013;time curve after the first dose because of the limited sampling duration.</p><p>At the MTD (280&#x000a0;mg/m<sup>2</sup>/dose) of crizotinib in children, the mean (&#x000b1;SD) <inline-formula id="IEq9"><alternatives><tex-math id="M17">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$ C_{\text{ave}}^{\text{ss}} $$\end{document}</tex-math><mml:math id="M18"><mml:msubsup><mml:mi>C</mml:mi><mml:mrow><mml:mtext>ave</mml:mtext></mml:mrow><mml:mtext>ss</mml:mtext></mml:msubsup></mml:math><inline-graphic xlink:href="280_2016_3220_Article_IEq9.gif"/></alternatives></inline-formula> is 580 (&#x000b1;170) ng/mL, and the mean <inline-formula id="IEq10"><alternatives><tex-math id="M19">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$ C_{{12{\text{h}}}}^{\text{ss}} $$\end{document}</tex-math><mml:math id="M20"><mml:msubsup><mml:mi>C</mml:mi><mml:mrow><mml:mrow><mml:mn>12</mml:mn><mml:mtext>h</mml:mtext></mml:mrow></mml:mrow><mml:mtext>ss</mml:mtext></mml:msubsup></mml:math><inline-graphic xlink:href="280_2016_3220_Article_IEq10.gif"/></alternatives></inline-formula> is 480 (&#x000b1;180) ng/mL. Plasma protein binding of crizotinib in adults is 90% [<xref ref-type="bibr" rid="CR9">9</xref>], and free <inline-formula id="IEq11"><alternatives><tex-math id="M21">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$ C_{\text{ave}}^{\text{ss}} $$\end{document}</tex-math><mml:math id="M22"><mml:msubsup><mml:mi>C</mml:mi><mml:mrow><mml:mtext>ave</mml:mtext></mml:mrow><mml:mtext>ss</mml:mtext></mml:msubsup></mml:math><inline-graphic xlink:href="280_2016_3220_Article_IEq11.gif"/></alternatives></inline-formula> and <inline-formula id="IEq12"><alternatives><tex-math id="M23">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$ C_{{12{\text{h}}}}^{\text{ss}} $$\end{document}</tex-math><mml:math id="M24"><mml:msubsup><mml:mi>C</mml:mi><mml:mrow><mml:mrow><mml:mn>12</mml:mn><mml:mtext>h</mml:mtext></mml:mrow></mml:mrow><mml:mtext>ss</mml:mtext></mml:msubsup></mml:math><inline-graphic xlink:href="280_2016_3220_Article_IEq12.gif"/></alternatives></inline-formula> are estimated to be 60 and 50&#x000a0;ng/mL, respectively. These free drug concentrations exceed the 10&#x000a0;ng/mL IC<sub>50</sub> of crizotinib in ALCL cell lines, Karpas299 and SU-DHL-1 that express the NPM-ALK fusion protein [<xref ref-type="bibr" rid="CR10">10</xref>], consistent with the high objective response rate to crizotinib in children with ALCL treated on the phase 1/2 trial even at doses below the MTD [<xref ref-type="bibr" rid="CR6">6</xref>].</p><p>The lactam metabolite of crizotinib, PF-06260182, is measurable in plasma, but at substantially lower concentrations than the parent drug [<xref ref-type="bibr" rid="CR8">8</xref>]. Although PF-06260182 is active, it is considerably less potent than crizotinib, and it is not thought to contribute significantly to the in vivo activity of crizotinib [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR11">11</xref>]. For this reason, we did not monitor PF-06260182 plasma concentrations in children.</p><p>In summary, the pharmacokinetics of oral crizotinib in children is similar to that in adults. A more palatable formulation is currently being evaluated in children. Clinical trials of crizotinib alone and in combination with chemotherapy in children with neuroblastoma, other solid tumors and ALCL are ongoing.</p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>ALCL</term><def><p>Anaplastic large-cell lymphoma</p></def></def-item><def-item><term>AUC</term><def><p>Area under the plasma concentration&#x02013;time curve</p></def></def-item><def-item><term><italic>C</italic><sub>12h</sub></term><def><p>Plasma concentration 12-h post-first dose (trough)</p></def></def-item><def-item><term><inline-formula id="IEq1"><alternatives><tex-math id="M25">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$ C_{{12{\text{h}}}}^{\text{ss}} $$\end{document}</tex-math><mml:math id="M26"><mml:msubsup><mml:mi>C</mml:mi><mml:mrow><mml:mrow><mml:mn>12</mml:mn><mml:mtext>h</mml:mtext></mml:mrow></mml:mrow><mml:mtext>ss</mml:mtext></mml:msubsup></mml:math><inline-graphic xlink:href="280_2016_3220_Article_IEq1.gif"/></alternatives></inline-formula></term><def><p>Plasma concentration 12-h post-dose (trough) at steady state</p></def></def-item><def-item><term><inline-formula id="IEq2"><alternatives><tex-math id="M27">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$ C_{\text{ave}}^{\text{ss}} $$\end{document}</tex-math><mml:math id="M28"><mml:msubsup><mml:mi>C</mml:mi><mml:mrow><mml:mtext>ave</mml:mtext></mml:mrow><mml:mtext>ss</mml:mtext></mml:msubsup></mml:math><inline-graphic xlink:href="280_2016_3220_Article_IEq2.gif"/></alternatives></inline-formula></term><def><p>Average plasma concentration at steady state</p></def></def-item><def-item><term>CL</term><def><p>Clearance</p></def></def-item><def-item><term>CL/F</term><def><p>Apparent clearance</p></def></def-item><def-item><term><italic>C</italic><sub>max</sub></term><def><p>Peak plasma concentration</p></def></def-item><def-item><term><inline-formula id="IEq3"><alternatives><tex-math id="M29">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$ C_{ \hbox{max} }^{\text{ss}} $$\end{document}</tex-math><mml:math id="M30"><mml:msubsup><mml:mi>C</mml:mi><mml:mrow><mml:mtext>max</mml:mtext></mml:mrow><mml:mtext>ss</mml:mtext></mml:msubsup></mml:math><inline-graphic xlink:href="280_2016_3220_Article_IEq3.gif"/></alternatives></inline-formula></term><def><p>Peak plasma concentration at steady state</p></def></def-item><def-item><term><italic>F</italic></term><def><p>Fraction of the dose that is absorbed (bioavailable)</p></def></def-item><def-item><term>FC</term><def><p>Formulated capsule</p></def></def-item><def-item><term>HPLC</term><def><p>High-pressure liquid chromatography</p></def></def-item><def-item><term>IRT</term><def><p>Immediate-release tablet</p></def></def-item><def-item><term>MTD</term><def><p>Maximum tolerated dose</p></def></def-item><def-item><term>NSCLC</term><def><p>Non-small-cell lung cancer</p></def></def-item><def-item><term>OS</term><def><p>Oral solution</p></def></def-item><def-item><term>PIB</term><def><p>Powder in bottle</p></def></def-item><def-item><term>PIC</term><def><p>Powder in capsule</p></def></def-item><def-item><term><italic>R</italic></term><def><p>Accumulation index</p></def></def-item><def-item><term><italic>&#x003c4;</italic></term><def><p>Dosing interval</p></def></def-item><def-item><term><italic>T</italic><sub>1/2</sub></term><def><p>Half-life</p></def></def-item><def-item><term><italic>t</italic><sub>last</sub></term><def><p>Time of last measured plasma concentration</p></def></def-item><def-item><term><italic>T</italic><sub>max</sub></term><def><p>Time post-dose that the <italic>C</italic>
<sub>max</sub> is reached</p></def></def-item></def-list></glossary><ack><title>Acknowledgements</title><p>Pfizer provided crizotinib for the trial and Covance Indianapolis performed the crizotinib HPLC/MS/MS assay with funding from Pfizer. The Children&#x02019;s Oncology Group held the IND under which this trial was conducted.</p><sec id="FPar1"><title>Funding</title><p>This clinical trial was supported by the National Cancer Institute (NCI) of the National Institutes of Health (NIH) [Award Number UM1 CA097452], Pfizer, Inc., Cookies for Kids&#x02019; Cancer Foundation, Alex&#x02019;s Lemonade Stand Center of Excellence grant, and the Children&#x02019;s Oncology Group.</p></sec></ack><notes notes-type="COI-statement"><title>Compliance with ethical standards</title><sec id="FPar2"><title>Conflict of interest</title><p>F. Balis has research funding from United Therapeutics Corp.; Y. Mosse has research funding from Pfizer, Inc. and Novartis; E. Fox has research funding from Glaxo Smith Kline, Merck and Incyta.</p></sec><sec id="FPar3"><title>Ethical approval</title><p>The phase 1 clinical trial of crizotinib was reviewed and approved by the Institutional Review Boards at each participating institution, and the clinical trial was conducted in accordance with the ethical standards outlined in the Declaration of Helsinki and the US Federal Regulations governing research in human subjects.</p></sec></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frampton</surname><given-names>JE</given-names></name></person-group><article-title>Crizotinib: a review of its use in the treatment of anaplastic lymphoma kinase-positive, advanced non-small cell lung cancer</article-title><source>Drugs</source><year>2013</year><volume>73</volume><issue>18</issue><fpage>2031</fpage><lpage>2051</lpage><pub-id pub-id-type="doi">10.1007/s40265-013-0142-z</pub-id><pub-id pub-id-type="pmid">24288180</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cappuzzo</surname><given-names>F</given-names></name><name><surname>Moro-Sibilot</surname><given-names>D</given-names></name><name><surname>Gautschi</surname><given-names>O</given-names></name><name><surname>Boleti</surname><given-names>E</given-names></name><name><surname>Felip</surname><given-names>E</given-names></name><name><surname>Groen</surname><given-names>HJ</given-names></name><name><surname>Germonpre</surname><given-names>P</given-names></name><name><surname>Meldgaard</surname><given-names>P</given-names></name><name><surname>Arriola</surname><given-names>E</given-names></name><name><surname>Steele</surname><given-names>N</given-names></name><name><surname>Fox</surname><given-names>J</given-names></name><name><surname>Schnell</surname><given-names>P</given-names></name><name><surname>Engelsberg</surname><given-names>A</given-names></name><name><surname>Wolf</surname><given-names>J</given-names></name></person-group><article-title>Management of crizotinib therapy for ALK-rearranged non-small cell lung carcinoma: an expert consensus</article-title><source>Lung Cancer</source><year>2015</year><volume>87</volume><issue>2</issue><fpage>89</fpage><lpage>95</lpage><pub-id pub-id-type="doi">10.1016/j.lungcan.2014.12.010</pub-id><pub-id pub-id-type="pmid">25576294</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Solomon</surname><given-names>BJ</given-names></name><name><surname>Mok</surname><given-names>T</given-names></name><name><surname>Kim</surname><given-names>DW</given-names></name><name><surname>Wu</surname><given-names>YL</given-names></name><name><surname>Nakagawa</surname><given-names>K</given-names></name><name><surname>Mekhail</surname><given-names>T</given-names></name><name><surname>Felip</surname><given-names>E</given-names></name><name><surname>Cappuzzo</surname><given-names>F</given-names></name><name><surname>Paolini</surname><given-names>J</given-names></name><name><surname>Usari</surname><given-names>T</given-names></name><name><surname>Iyer</surname><given-names>S</given-names></name><name><surname>Reisman</surname><given-names>A</given-names></name><name><surname>Wilner</surname><given-names>KD</given-names></name><name><surname>Tursi</surname><given-names>J</given-names></name><name><surname>Blackhall</surname><given-names>F</given-names></name></person-group><article-title>First-line crizotinib versus chemotherapy in ALK-positive lung cancer</article-title><source>N Engl J Med</source><year>2014</year><volume>371</volume><issue>23</issue><fpage>2167</fpage><lpage>2177</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1408440</pub-id><pub-id pub-id-type="pmid">25470694</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Camidge</surname><given-names>DR</given-names></name><name><surname>Bang</surname><given-names>YJ</given-names></name><name><surname>Kwak</surname><given-names>EL</given-names></name><name><surname>Iafrate</surname><given-names>AJ</given-names></name><name><surname>Varella-Garcia</surname><given-names>M</given-names></name><name><surname>Fox</surname><given-names>SB</given-names></name><name><surname>Riely</surname><given-names>GJ</given-names></name><name><surname>Solomon</surname><given-names>B</given-names></name><name><surname>Ou</surname><given-names>SH</given-names></name><name><surname>Kim</surname><given-names>DW</given-names></name><name><surname>Salgia</surname><given-names>R</given-names></name><name><surname>Fidias</surname><given-names>P</given-names></name><name><surname>Engelman</surname><given-names>JA</given-names></name><name><surname>Gandhi</surname><given-names>L</given-names></name><name><surname>Janne</surname><given-names>PA</given-names></name><name><surname>Costa</surname><given-names>DB</given-names></name><name><surname>Shapiro</surname><given-names>GI</given-names></name><name><surname>Lorusso</surname><given-names>P</given-names></name><name><surname>Ruffner</surname><given-names>K</given-names></name><name><surname>Stephenson</surname><given-names>P</given-names></name><name><surname>Tang</surname><given-names>Y</given-names></name><name><surname>Wilner</surname><given-names>K</given-names></name><name><surname>Clark</surname><given-names>JW</given-names></name><name><surname>Shaw</surname><given-names>AT</given-names></name></person-group><article-title>Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study</article-title><source>Lancet Oncol</source><year>2012</year><volume>13</volume><issue>10</issue><fpage>1011</fpage><lpage>1019</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(12)70344-3</pub-id><pub-id pub-id-type="pmid">22954507</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gambacorti-Passerini</surname><given-names>C</given-names></name><name><surname>Messa</surname><given-names>C</given-names></name><name><surname>Pogliani</surname><given-names>EM</given-names></name></person-group><article-title>Crizotinib in anaplastic large-cell lymphoma</article-title><source>N Engl J Med</source><year>2011</year><volume>364</volume><issue>8</issue><fpage>775</fpage><lpage>776</lpage><pub-id pub-id-type="doi">10.1056/NEJMc1013224</pub-id><pub-id pub-id-type="pmid">21345110</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mosse</surname><given-names>YP</given-names></name><name><surname>Lim</surname><given-names>MS</given-names></name><name><surname>Voss</surname><given-names>SD</given-names></name><name><surname>Wilner</surname><given-names>K</given-names></name><name><surname>Ruffner</surname><given-names>K</given-names></name><name><surname>Laliberte</surname><given-names>J</given-names></name><name><surname>Rolland</surname><given-names>D</given-names></name><name><surname>Balis</surname><given-names>FM</given-names></name><name><surname>Maris</surname><given-names>JM</given-names></name><name><surname>Weigel</surname><given-names>BJ</given-names></name><name><surname>Ingle</surname><given-names>AM</given-names></name><name><surname>Ahern</surname><given-names>C</given-names></name><name><surname>Adamson</surname><given-names>PC</given-names></name><name><surname>Blaney</surname><given-names>SM</given-names></name></person-group><article-title>Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children&#x02019;s Oncology Group phase 1 consortium study</article-title><source>Lancet Oncol</source><year>2013</year><volume>14</volume><issue>6</issue><fpage>472</fpage><lpage>480</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(13)70095-0</pub-id><pub-id pub-id-type="pmid">23598171</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murga-Zamalloa</surname><given-names>C</given-names></name><name><surname>Lim</surname><given-names>MS</given-names></name></person-group><article-title>ALK-driven tumors and targeted therapy: focus on crizotinib</article-title><source>Pharmacogenomics Pers Med</source><year>2014</year><volume>7</volume><fpage>87</fpage><lpage>94</lpage></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>H</given-names></name><name><surname>O&#x02019;Gorman</surname><given-names>M</given-names></name><name><surname>Boutros</surname><given-names>T</given-names></name><name><surname>Brega</surname><given-names>N</given-names></name><name><surname>Kantaridis</surname><given-names>C</given-names></name><name><surname>Tan</surname><given-names>W</given-names></name><name><surname>Bello</surname><given-names>A</given-names></name></person-group><article-title>Evaluation of crizotinib absolute bioavailability, the bioequivalence of three oral formulations, and the effect of food on crizotinib pharmacokinetics in healthy subjects</article-title><source>J Clin Pharmacol</source><year>2015</year><volume>55</volume><issue>1</issue><fpage>104</fpage><lpage>113</lpage><pub-id pub-id-type="doi">10.1002/jcph.356</pub-id><pub-id pub-id-type="pmid">24990113</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hamilton</surname><given-names>G</given-names></name><name><surname>Rath</surname><given-names>B</given-names></name><name><surname>Burghuber</surname><given-names>O</given-names></name></person-group><article-title>Pharmacokinetics of crizotinib in NSCLC patients</article-title><source>Expert Opin Drug Metab Toxicol</source><year>2015</year><volume>11</volume><issue>5</issue><fpage>835</fpage><lpage>842</lpage><pub-id pub-id-type="doi">10.1517/17425255.2015.1021685</pub-id><pub-id pub-id-type="pmid">25732197</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Christensen</surname><given-names>JG</given-names></name><name><surname>Zou</surname><given-names>HY</given-names></name><name><surname>Arango</surname><given-names>ME</given-names></name><name><surname>Li</surname><given-names>Q</given-names></name><name><surname>Lee</surname><given-names>JH</given-names></name><name><surname>McDonnell</surname><given-names>SR</given-names></name><name><surname>Yamazaki</surname><given-names>S</given-names></name><name><surname>Alton</surname><given-names>GR</given-names></name><name><surname>Mroczkowski</surname><given-names>B</given-names></name><name><surname>Los</surname><given-names>G</given-names></name></person-group><article-title>Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma</article-title><source>Mol Cancer Ther</source><year>2007</year><volume>6</volume><issue>12 Pt 1</issue><fpage>3314</fpage><lpage>3322</lpage><pub-id pub-id-type="doi">10.1158/1535-7163.MCT-07-0365</pub-id><pub-id pub-id-type="pmid">18089725</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname><given-names>TR</given-names></name><name><surname>Tan</surname><given-names>W</given-names></name><name><surname>Goulet</surname><given-names>L</given-names></name><name><surname>Smith</surname><given-names>EB</given-names></name><name><surname>Yamazaki</surname><given-names>S</given-names></name><name><surname>Walker</surname><given-names>GS</given-names></name><name><surname>O&#x02019;Gorman</surname><given-names>MT</given-names></name><name><surname>Bedarida</surname><given-names>G</given-names></name><name><surname>Zou</surname><given-names>HY</given-names></name><name><surname>Christensen</surname><given-names>JG</given-names></name><name><surname>Nguyen</surname><given-names>LN</given-names></name><name><surname>Shen</surname><given-names>Z</given-names></name><name><surname>Dalvie</surname><given-names>D</given-names></name><name><surname>Bello</surname><given-names>A</given-names></name><name><surname>Smith</surname><given-names>BJ</given-names></name></person-group><article-title>Metabolism, excretion and pharmacokinetics of [14C]crizotinib following oral administration to healthy subjects</article-title><source>Xenobiotica</source><year>2015</year><volume>45</volume><issue>1</issue><fpage>45</fpage><lpage>59</lpage><pub-id pub-id-type="doi">10.3109/00498254.2014.941964</pub-id><pub-id pub-id-type="pmid">25034009</pub-id></element-citation></ref></ref-list></back></article>